Market Access and Reimbursement Risk Assessment.
Built by former payers, HTA reviewers, and Industry Experts.
Understanding how different markets and product types shape pricing, reimbursement, and access strategies. Global Market Access Models (Short “How It Works” Overviews) United States Europe / HTA-driven systems (conceptual) Japan
What Is Market Access in Pharma, Why It Matters, and How Disciplines and Stakeholders Intersect Executive Summary Market access is the set of activities that ensure a medicine is
Market Access Across the Development Pathway includes Discovery / Pre-clinical: early unmet need mapping; target product profile (TPP) with payer-relevant claims; landscape scan (customers, competition, context). Phase 1–2: endpoint selection
Learn how MARA Rating’s Uncertainty & Sensitivity domain (A++–C) predicts HTA outcomes; why 2.6 vs 2.0 scores sway payer trust, pricing & reimbursement. Since 2020, we’ve seen a clear split:
How Evidence Quality Scores Impact HTA Assessment Success: The 2.9 Benchmark Since 2020, assets with an average Evidence Quality score of 2.9 have sailed through HTA assessments more regularly than
Many breakthrough therapies in the U.S. stumble in their first year on the market, despite strong clinical promise. The reason isn’t usually safety or efficacy. It’s cost pressures, evidence maturity, and system
About MARA Rating: We provide an independent Market‑Access Risk Assessment (A++ → C) built on a transparent, 10‑domain HTA framework. Use the score to benchmark an asset’s access prospects against
MARA Rating Insight: Why Resource Use & Cost Implications Decide Coverage Since 2020, one pattern has been clear in our database: Assets averaging 2.8 in Resource Use & Cost progressed through HTA
MARA Rating’s Care Pathway Integration score (A++–C) predicts HTA endorsement and payer adoption by measuring clinical guideline alignment, workflow efficiency, administration ease, and implementation feasibility. Too often, M&A teams under-weight
MARA Rating’s Patient Population score (A++–C) predicts HTA approval & reimbursement success. Learn how robust subgroup analysis and real-world evidence drive payer confidence. Too often, M&A teams under-weight market-access risk—patient